Evidence map›Paper›PMID 38761461›Full record

ArticleThe International journal on drug policy2024

Safety strategies and harm reduction for methamphetamine users in the era of fentanyl contamination: A qualitative analysis.

Olufemi Erinoso, Robbie Daugherty, Mia R Kirk, Robert W Harding, Haley Etchart, Andres Reyes, Kimberly Page, Phillip Fiuty, Karla D Wagner

Abstract read
In one paragraph

Article in The International journal on drug policy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Olufemi ErinosoDepartment of Health Behavior, Policy and Administration Sciences, School of Public Health, University of Nevada, Reno, United States.
Robbie DaughertyDepartment of Health Behavior, Policy and Administration Sciences, School of Public Health, University of Nevada, Reno, United States.
Mia R KirkDepartment of Health Behavior, Policy and Administration Sciences, School of Public Health, University of Nevada, Reno, United States.
Robert W HardingDepartment of Health Behavior, Policy and Administration Sciences, School of Public Health, University of Nevada, Reno, United States.
Haley EtchartDepartment of Health Behavior, Policy and Administration Sciences, School of Public Health, University of Nevada, Reno, United States.
Andres ReyesDepartment of Internal Medicine, University of New Mexico Health Sciences, Albuquerque, NM, United States.
Kimberly PageDepartment of Internal Medicine, University of New Mexico Health Sciences, Albuquerque, NM, United States.
Phillip FiutyNew Mexico Health, Albuquerque, New Mexico, United States.
Karla D WagnerDepartment of Health Behavior, Policy and Administration Sciences, School of Public Health, University of Nevada, Reno, United States. Electronic address: karlawagner@unr.edu.

Funding

A Multi-Site Mixed Methods Study of Methamphetamine Use in the Mountain WestR01CE003356 · CE · UNIVERSITY OF NEVADA RENO · PI PAGE, KIMBERLY, WAGNER, KARLA D. · 2021 to 2023
$1.1M
NCIPC CDC HHS R01 CE003356
6 · The paper itself

Abstract

introductionIn the United States, methamphetamine use is increasing and the context of its use has changed, with reports of illicitly manufactured fentanyl being mixed with methamphetamine (either deliberately or inadvertently). We explore risk-mitigating actions taken by people who use drugs to protect their health when using methamphetamine in that context.

methodsWe conducted qualitative interviews with 48 adults (18+) who used methamphetamine in the past three months at two sites in Nevada, USA and two sites in New Mexico, USA. Interviews were recorded, transcribed, and analyzed using thematic analysis.

resultsRespondents described two rationales for employing harm reduction strategies. First, to prevent harm from methamphetamine containing illicit fentanyl, and second, to maintain their general wellbeing while using methamphetamine. Regarding methamphetamine containing illicit fentanyl, our findings highlight how respondents employ primary strategies like buying from trusted sources and secondary strategies such as spotting and selective use of harm reduction tools (i.e., fentanyl test strips) to reduce risks. To maintain their general wellbeing, participants reduced their use of methamphetamine as reasonably as possible, and used other substances like marijuana and alcohol alongside methamphetamine to counter the unwanted side effects of methamphetamine (i.e., hallucinations and paranoia). Use of these harm reduction strategies varied within situational and social contexts, and respondents usually developed these strategies based on their lived experiences.

conclusionOur findings uniquely demonstrate that people who use methamphetamine prioritize community driven, trust-based strategies within their social networks to mitigate risks in a fentanyl-contaminated drug environment. Additionally, our results indicate that harm reduction behaviors are influenced by multilevel risk environments, which include social, physical, economic, and political factors. Overall, these results highlight the potential for targeted interventions at the network level, which are responsive to complexities and shifts in drug market dynamics- such as illicit fentanyl in methamphetamine.

Indexed as

Amphetamine-Related DisordersDrug ContaminationFentanylHarm ReductionMethamphetamineAdultFemaleHumansIllicit DrugsInterviews as TopicMaleMiddle AgedNevadaNew MexicoQualitative ResearchYoung AdultFentanylIllicit DrugsMethamphetamineFentanylHarm reductionMethamphetamineOpioidsOverdoseQualitative methodsToxicity

Identifiers

PMID38761461
PMCPMC11590564

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.